Menu Close

Acrivastine Brand And Generic Names

Acrivastine substance is a white crystalline odorless powder, soluble in alcohol and chloroform, sparingly soluble in water. Blocker of histamine H1-receptors. Antiallergic agent.

Pharmacological action

Acrivastine shows antiallergic, antiexudative, antihistaminic action. Acrivastine reduces or eliminates the symptoms of such conditions that are wholly or partly connected to the release of histamine. Histamine is a substance which is released in excessive amounts in the body in allergic reactions and diseases that lead to rashes, itching, swelling of the skin and mucous membranes. Acrivastine cause symptomatic improvement in conditions that are partially or entirely due to a triggering mechanism of histamine release. Acrivastine blocks the action of histamine and relieves the symptoms of allergies. The agent blocks histamine H1-receptors, reduces the body's response to histamine, reduces capillary permeability and exudation. Acrivastine prevents the development and facilitates the course of allergic reactions. It weakens the symptoms of seasonal allergic rhinitis (runny nose, sneezing, itching, watery eyes). After receiving a single dose of 8 mg, Acrivastine shows effect in adults during the first 30 min; the maximum effect on the skin manifestations (rash, redness) is observed within 1.5-2 h after administration. Reducing manifestations of allergic rhinitis is observed within 1 hour after intake. After that, the activity is gradually decreased, but high antihistaminic activity is maintained for 12 hours after dosing. The agent has weak cholinolytic and sedative effect. Acrivastine is a highly effective drug, and it also significantly reduces congestion and blistering. In cases of intermittent treatment, Acrivastine is preferred because of the rapidity of effect and a short period of action, allowing a flexible dosing regimen.

Experimental studies found no carcinogenic, mutagenic effects and impact on fertility.

Acrivastine is well absorbed (food intake does not affect the AUC) and relatively evenly distributed in the body; does not penetrate the blood-brain barrier. The agent slightly metabolizes to the active metabolite (propionic acid analogue), whose concentration in plasma is 10% of the level of the drug. Plasma protein binding is 48-52%. When multiple doses for 6 days, Acrivastine cumulation is not observed. Acrivastine is excreted in the urine and by the kidneys within 48 hours (mostly unchanged). No significant differences were observed in pharmacokinetic parameters in patients of different age, gender and race. The drug does not accumulate in the body during long-term treatment.

Administration of Acrivastine

Acrivastine is used in allergic rhinitis, hay fever, allergic dermatitis, atopic eczema, symptomatic dermographism, urticaria (chronic idiopathic, cholinergic, cold).

Acrivastine is a good assistant for allergies, but its reception should be systemic and appointed by the doctor. Take the drug only after the doctor's appointment - he will make an individual regimen for each patient.


Moderate or severe renal insufficiency (creatinine clearance <50 mL/min or serum creatinine content of more than 150 mmol/L), increased sensitivity to Acrivastine or triprolidine, pregnancy (possible only if the effect of therapy outweighs the potential risk to the fetus), lactation, children (under 12 years).

Pregnancy and breast-feeding

It is contraindicated to take Acrivastine during pregnancy. At the time of treatment patients should stop breastfeeding.

Side effects of Acrivastine

The majority of patients receiving Acrivastine do not suffer from any adverse reactions. In extremely rare cases the drug may cause drowsiness and rash. However, like other drugs, Acrivastine may cause some allergic reaction. When symptoms of allergy occur (asthma attack, chest tightness, swelling of the eyelids, lips, face, mucous membranes of the mouth or tongue, rash or hives), stop taking the drug and contact your doctor immediately.

From the nervous system and sensory organs: rarely - headache, dizziness, nervousness, insomnia, drowsiness, decrease in the rate of mental and motor responses, impaired attention.

Allergic reactions: seldom - anaphylaxis, angioedema, bronchospasm, erythema multiforme.

From the digestive tract: rarely - dry mouth, nausea, dyspepsia.

Other: pharyngitis, dysmenorrhea.

Drug interaction

Alcohol and other CNS depressants may increase the influence on the central nervous system (such combination is not recommended). Simultaneous use of Acrivastine and drugs that have a depressing effect on the CNS or with ethanol may increase impaired ability to concentrate and decrease the speed of psychomotor reactions.
The effect of acarbose may weaken while the use of antacids, bile acid sequestrants, enterosorbents and digestive enzymes.
Concomitant use with Alprazolam worsens functioning of the CNS and reduces psychomotor speed reactions. Biperiden enhances (mutually) cholinolytic effect; possible development of the central anticholinergic syndrome (atropine intoxication). Buprenorphine enhances (mutually) CNS depression. Acrivastine reduces the anticoagulant effect of heparin sodium.


Overdose may include the following symptoms: disorder of the gastrointestinal tract, headache, drowsiness, weakness, pallor, insomnia, fear, anxiety, agitation, tremors, convulsions, dysuria, arrhythmia, collapse.

If you accidentally took the dose that exceeds recommended, consult a doctor. Prior to the examination the doctor patient can cause vomiting or gastric lavage.

Treatment: symptomatic and supportive therapy.

Dosing and administration

Take orally, adults and children over 12 years - 8 mg 3 times a day (1 capsule 2 to 3 times per day), regardless of the meal, with water. Elderly: the drug is recommended in normal doses. However, patients with impaired renal function should be consulted by a doctor. Duration of treatment is determined individually.

Skipping a single dose. If you forget to take the next dose, take it as soon as you remember about it and then continue treatment in the usual way.


Acrivastine may affect the psychophysical capacity, reducing the concentration and delaying responses. Most patients do not feel drowsiness, but there may be individual response to the drug. If you are engaged in activities requiring alertness and fast reaction (e.g. driving a car or working with complicated equipment), care must be taken after receiving the drug, until you find out whether Acrivastine intake causes drowsiness or not. In appointing in elderly patients, monitoring of renal function is recommended.

No data currently available on the safety of Acrivastine in children under 12 years.

Storage conditions

Keep Acrivastine at a temperature not exceeding 30°C in a dry and dark place.
Keep Acrivastine and other drugs out of the reach of children.
Do not use the medication after the expiration date printed on the package.
Expand description..
Your search did not return any results. Try adjusting your search values.

Click here to go back.